725 reports of this reaction
1.7% of all METHYLPREDNISOLONE ACETATE reports
#10 most reported adverse reaction
DRUG HYPERSENSITIVITY is the #10 most commonly reported adverse reaction for METHYLPREDNISOLONE ACETATE, manufactured by Pharmacia & Upjohn Company LLC. There are 725 FDA adverse event reports linking METHYLPREDNISOLONE ACETATE to DRUG HYPERSENSITIVITY. This represents approximately 1.7% of all 42,188 adverse event reports for this drug.
Patients taking METHYLPREDNISOLONE ACETATE who experience drug hypersensitivity should discuss this symptom with their healthcare provider to determine whether it may be related to their medication and what alternatives may be available.
DRUG HYPERSENSITIVITY is a less commonly reported adverse event for METHYLPREDNISOLONE ACETATE, but still significant enough to appear in the safety profile.
In addition to drug hypersensitivity, the following adverse reactions have been reported for METHYLPREDNISOLONE ACETATE:
The following drugs have also been linked to drug hypersensitivity in FDA adverse event reports:
DRUG HYPERSENSITIVITY has been reported as an adverse event in 725 FDA reports for METHYLPREDNISOLONE ACETATE. This does not prove causation, but indicates an association observed in post-market surveillance data.
DRUG HYPERSENSITIVITY accounts for approximately 1.7% of all adverse event reports for METHYLPREDNISOLONE ACETATE, making it a notable side effect.
If you experience drug hypersensitivity while taking METHYLPREDNISOLONE ACETATE, contact your healthcare provider. They can evaluate whether the symptom is related to your medication and discuss potential adjustments to your treatment plan. Do not stop taking prescribed medication without consulting your doctor.